Pharmaceutical News

RSS

Vanda, Biotoscana Farma partner to commercialize Fanapt in Argentina

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Argentina-based Biotoscana Farma S.A., a wholly owned affiliate of Biotoscana International, based in Bogota, Colombia, for the commercialization of Fanapt ™ in Argentina.

1 Aug 2011

Merck submits ridaforolimus MAA with EMA for treatment of metastatic soft-tissue, bone sarcomas

ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.

1 Aug 2011

Fischer retains TransMedia to launch Israel's most popular sunscreen in the U.S.

Fischer Pharmaceutical Ltd., a multi-national company specializing in R&D and manufacture of a wide variety of skin and health care products, has retained TransMedia Group to introduce Israel's most popular sunscreen, Dr. Fischer ULTRASOL, in the United States.

1 Aug 2011

Universal flu vaccine based on “super antibody” coming soon

Researchers have finally found the first antibody which can fight all types of the influenza A virus. The results of the experiments on flu-infected mice, published in Science Express, showed the antibody could be used as an “emergency treatment” for flu as well.

31 Jul 2011

Demonstrators in Swaziland express concern over possible antiretroviral shortages

More than 3,000 demonstrators gathered across Swaziland on Thursday for a second day of protests over the king's handling of an economic crisis that they say is causing a shortage of medical supplies, including antiretroviral therapy, the Associated Press/Washington Post reports (7/28).

30 Jul 2011

Labopharm, Angelini enter into agreement to reorganize partnership

Labopharm Inc. and Gruppo Angelini, its partner in the joint venture established by the two companies to commercialize OLEPTRO in the U.S., today announced that they have entered into an agreement to restructure their partnership.

30 Jul 2011

U.S. appeals court rules in favor of Lilly over Strattera patent case

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has overturned a prior ruling by the U.S. District Court for the District of New Jersey and has upheld the validity of the company's method-of-use patent on Strattera.

30 Jul 2011

PPTA applauds introduction of 'Preserving Access to Orphan Drugs Act'

The Plasma Protein Therapeutics Association (PPTA) applauds the introduction of bipartisan legislation, the Preserving Access to Orphan Drugs Act (H.R. 2672) and (S. 1423), which will safeguard the development of drugs and therapies that treat patients with rare diseases by eliminating barriers to innovation.

30 Jul 2011

AHRQ: Average annual prescription drug expenses for children with asthma have doubled

The percentage of American children treated for asthma increased while their annual drug expenses more than doubled over a 10-year period, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

30 Jul 2011

LA Times: Robots and pharmacies

At Molina Medical Group clinics in Southern California, a vending machine rather than a pharmacist dispenses prescription drugs. Molina officials say the machines make life simpler for patients, but their use has drawn objections from some pharmacists.

30 Jul 2011

Lupin, Lilly partner to promote and distribute Huminsulin products in India and Nepal

Eli Lilly India and Lupin Limited today announced they have entered into a strategic collaboration to promote and distribute Lilly's Huminsulin range of products, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, Huminsulin 30/70 and Humapen Ergo II.

30 Jul 2011

Humira defect lawyers file lawsuit against Abbott in Texas state court

Humira defect lawyers filed a lawsuit against Abbott Laboratories in Texas state court claiming Abbott's blockbuster drug, Humira, caused a life-threatening disease, leukemia.

30 Jul 2011

Pharmalucence selects Bosch to provide isolated filling line for Billerica production facility

Pharmalucence, Inc. has selected Robert Bosch Packaging Technology, Inc. to provide a state-of-the-art isolated pharmaceutical filling line for the new Pharmalucence production facility being constructed in Billerica, MA.

30 Jul 2011

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

Pfizer Inc today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company's supplemental Biologics License Application (sBLA) for use of Prevnar 13, in adults aged 50 and older.

30 Jul 2011

WARFARIN Study initiated to assess utility of genetic testing to reduce warfarin-related adverse events

Iverson Genetic Diagnostics, Inc. announced that the WARFARIN Study was initiated at Colorado Heart & Vascular, P.C. in Denver and other major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events.

30 Jul 2011

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of ORENCIA (abatacept) for the treatment of adults with moderate to severe rheumatoid arthritis.

30 Jul 2011

Researchers examine drug that has potential to stop Parkinson's progression

Researchers from Michigan State University's College of Human Medicine, Van Andel Research Institute and the Translational Genomics Research Institute are investigating a drug that has the potential to not only alleviate Parkinson's symptoms but also halt the disease's progression.

30 Jul 2011

CJ, RaQualia sign license agreement to develop and commercialize RQ-00000010 Partial Agonist

RaQualia Pharma Inc. today announced the signing of a license agreement with CJ CheilJedang Co. (CJ), granting CJ exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 Partial Agonist in Korea, China, Taiwan, India and Southeast Asia.

30 Jul 2011

FDA approves Lannett's ANDA for Phentermine Resin Extended-Release Capsules

Lannett Company, Inc. today announced the U.S. Food and Drug Administration (FDA) approved its Abbreviated New Drug Application (ANDA) for Phentermine Resin Extended-Release Capsules, 15 mg and 30 mg, representing the fourth product approval the company has received in the last five weeks.

29 Jul 2011

Cadence confirms FDA dosing recommendations for OFIRMEV

Cadence Pharmaceuticals, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) approved dosing recommendations for OFIRMEV (acetaminophen) injection remains 4,000 mg per day for adults and adolescents weighing at least 50 kg.

29 Jul 2011

Pharmaceutical News

Vanda, Biotoscana Farma partner to commercialize Fanapt in Argentina

Merck submits ridaforolimus MAA with EMA for treatment of metastatic soft-tissue, bone sarcomas

Fischer retains TransMedia to launch Israel's most popular sunscreen in the U.S.

Universal flu vaccine based on “super antibody” coming soon

Demonstrators in Swaziland express concern over possible antiretroviral shortages

Labopharm, Angelini enter into agreement to reorganize partnership

U.S. appeals court rules in favor of Lilly over Strattera patent case

PPTA applauds introduction of 'Preserving Access to Orphan Drugs Act'

AHRQ: Average annual prescription drug expenses for children with asthma have doubled

LA Times: Robots and pharmacies

Lupin, Lilly partner to promote and distribute Huminsulin products in India and Nepal

Humira defect lawyers file lawsuit against Abbott in Texas state court

Pharmalucence selects Bosch to provide isolated filling line for Billerica production facility

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

WARFARIN Study initiated to assess utility of genetic testing to reduce warfarin-related adverse events

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

Researchers examine drug that has potential to stop Parkinson's progression

CJ, RaQualia sign license agreement to develop and commercialize RQ-00000010 Partial Agonist

FDA approves Lannett's ANDA for Phentermine Resin Extended-Release Capsules

Cadence confirms FDA dosing recommendations for OFIRMEV

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News